

HOUSE OF REPRESENTATIVES

EIGHTY-NINTH SESSION

H. F. No. 1376

03/02/2015 Authored by Barrett
The bill was read for the first time and referred to the Committee on Public Safety and Crime Prevention Policy and Finance
03/23/2015 Adoption of Report: Placed on the General Register
Read Second Time
04/29/2015 Referred to the Chief Clerk for Comparison with S. F. No. 1219
04/30/2015 Postponed Indefinitely

1.1 A bill for an act
1.2 relating to health; modifying the schedules of controlled substances; amending
1.3 Minnesota Statutes 2014, section 152.02, subdivisions 2, 3, 4, 5, 6.
1.4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.5 Section 1. Minnesota Statutes 2014, section 152.02, subdivision 2, is amended to read:

1.6 Subd. 2. **Schedule I.** (a) Schedule I consists of the substances listed in this
1.7 subdivision.

1.8 (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of
1.9 the following substances, including their analogs, isomers, esters, ethers, salts, and salts
1.10 of isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters,
1.11 ethers, and salts is possible:

1.12 (1) acetylmethadol;

1.13 (2) allylprodine;

1.14 (3) alphacetylmethadol (except levo-alphacetylmethadol, also known as
1.15 levomethadyl acetate);

1.16 (4) alphameprodine;

1.17 (5) alphasmethadol;

1.18 (6) alpha-methylfentanyl benzethidine;

1.19 (7) betacetylmethadol;

1.20 (8) betameprodine;

1.21 (9) betamethadol;

1.22 (10) betaproline;

1.23 (11) clonitazene;

1.24 (12) dextromoramide;

- 2.1 (13) diampromide;
- 2.2 (14) diethylambutene;
- 2.3 (15) difenoxin;
- 2.4 (16) dimenoxadol;
- 2.5 (17) dimepheptanol;
- 2.6 (18) dimethylambutene;
- 2.7 (19) dioxaphetyl butyrate;
- 2.8 (20) dipipanone;
- 2.9 (21) ethylmethylthiambutene;
- 2.10 (22) etonitazene;
- 2.11 (23) etoxeridine;
- 2.12 (24) furethidine;
- 2.13 (25) hydroxypethidine;
- 2.14 (26) ketobemidone;
- 2.15 (27) levomoramide;
- 2.16 (28) levophenacylmorphane;
- 2.17 (29) 3-methylfentanyl;
- 2.18 (30) acetyl-alpha-methylfentanyl;
- 2.19 (31) alpha-methylthiofentanyl;
- 2.20 (32) benzylfentanyl beta-hydroxyfentanyl;
- 2.21 (33) beta-hydroxy-3-methylfentanyl;
- 2.22 (34) 3-methylthiofentanyl;
- 2.23 (35) thenylfentanyl;
- 2.24 (36) thiofentanyl;
- 2.25 (37) para-fluorofentanyl;
- 2.26 (38) morpheridine;
- 2.27 (39) 1-methyl-4-phenyl-4-propionoxypiperidine;
- 2.28 (40) noracymethadol;
- 2.29 (41) norlevorphanol;
- 2.30 (42) normethadone;
- 2.31 (43) norpipanone;
- 2.32 (44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
- 2.33 (45) phenadoxone;
- 2.34 (46) phenampromide;
- 2.35 (47) phenomorphan;
- 2.36 (48) phenoperidine;

- 3.1 (49) piritramide;
- 3.2 (50) proheptazine;
- 3.3 (51) properidine;
- 3.4 (52) propiram;
- 3.5 (53) racemoramide;
- 3.6 (54) tilidine;
- 3.7 (55) trimeperidine;
- 3.8 (56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl).

3.9 (c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,
3.10 and salts of isomers, unless specifically excepted or unless listed in another schedule,
3.11 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

- 3.12 (1) acetorphine;
- 3.13 (2) acetyldihydrocodeine;
- 3.14 (3) benzylmorphine;
- 3.15 (4) codeine methylbromide;
- 3.16 (5) codeine-n-oxide;
- 3.17 (6) cyprenorphine;
- 3.18 (7) desomorphine;
- 3.19 (8) dihydromorphine;
- 3.20 (9) drotebanol;
- 3.21 (10) etorphine;
- 3.22 (11) heroin;
- 3.23 (12) hydromorphenol;
- 3.24 (13) methyl-desorphine;
- 3.25 (14) methyldihydromorphine;
- 3.26 (15) morphine methylbromide;
- 3.27 (16) morphine methylsulfonate;
- 3.28 (17) morphine-n-oxide;
- 3.29 (18) myrophine;
- 3.30 (19) nicocodeine;
- 3.31 (20) nicomorphine;
- 3.32 (21) normorphine;
- 3.33 (22) pholcodine;
- 3.34 (23) thebacon.

3.35 (d) Hallucinogens. Any material, compound, mixture or preparation which contains
3.36 any quantity of the following substances, their analogs, salts, isomers (whether optical,

positional, or geometric), and salts of isomers, unless specifically excepted or unless listed in another schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

- (1) methylenedioxy amphetamine;
- (2) methylenedioxymethamphetamine;
- (3) methylenedioxy-N-ethylamphetamine (MDEA);
- (4) n-hydroxy-methylenedioxyamphetamine;
- (5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
- (6) 2,5-dimethoxyamphetamine (2,5-DMA);
- (7) 4-methoxyamphetamine;
- (8) 5-methoxy-3, 4-methylenedioxyamphetamine;
- (9) alpha-ethyltryptamine;
- (10) bufotenine;
- (11) diethyltryptamine;
- (12) dimethyltryptamine;
- (13) 3,4,5-trimethoxyamphetamine;
- (14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
- (15) ibogaine;
- (16) lysergic acid diethylamide (LSD);
- (17) mescaline;
- (18) parahexyl;
- (19) N-ethyl-3-piperidyl benzilate;
- (20) N-methyl-3-piperidyl benzilate;
- (21) psilocybin;
- (22) psilocyn;
- (23) tenocyclidine (TPCP or TCP);
- (24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
- (25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
- (26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
- (27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
- (28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
- (29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
- (30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
- (31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
- (32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
- (33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);

- 5.1 (34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
- 5.2 (35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
- 5.3 (36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
- 5.4 (37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
- 5.5 (38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
- 5.6 (2-CB-FLY);
- 5.7 (39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
- 5.8 (40) alpha-methyltryptamine (AMT);
- 5.9 (41) N,N-diisopropyltryptamine (DiPT);
- 5.10 (42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
- 5.11 (43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
- 5.12 (44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
- 5.13 (45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
- 5.14 (46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
- 5.15 (47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
- 5.16 (48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
- 5.17 (49) 5-methoxy- α -methyltryptamine (5-MeO-AMT);
- 5.18 (50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 5.19 (51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
- 5.20 (52) 5-methoxy-N-methyl-N-propyltryptamine (5-MeO-MiPT);
- 5.21 (53) 5-methoxy- α -ethyltryptamine (5-MeO-AET);
- 5.22 (54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
- 5.23 (55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
- 5.24 (56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
- 5.25 (57) methoxetamine (MXE);
- 5.26 (58) 5-iodo-2-aminoindane (5-IAI);
- 5.27 (59) 5,6-methylenedioxy-2-aminoindane (MDAI);
- 5.28 ~~(60) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine~~
- 5.29 (60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
- 5.30 (25B-NBOMe);
- 5.31 (61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
- 5.32 (25C-NBOMe);
- 5.33 (62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
- 5.34 (25I-NBOMe);
- 5.35 (63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
- 5.36 (64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);

(e) Peyote. All parts of the plant presently classified botanically as *Lophophora williamsii* Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant, and every compound, manufacture, salts, derivative, mixture, or preparation of the plant, its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian Church, and members of the American Indian Church are exempt from registration. Any person who manufactures peyote for or distributes peyote to the American Indian Church, however, is required to obtain federal registration annually and to comply with all other requirements of law.

(f) Central nervous system depressants. Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

- (1) mecloqualone;
- (2) methaqualone;
- (3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
- (4) flunitrazepam.

(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

- (1) aminorex;
- (2) cathinone;
- (3) fenethylline;
- (4) methcathinone;
- (5) methylaminorex;
- (6) N,N-dimethylamphetamine;
- (7) N-benzylpiperazine (BZP);
- (8) methylmethcathinone (mephedrone);
- (9) 3,4-methylenedioxy-N-methylcathinone (methydone);
- (10) methoxymethcathinone (methedrone);
- (11) methylenedioxypyrovalerone (MDPV);
- (12) ~~fluoromethcathinone~~ 3-fluoro-N-methylcathinone (3-FMC);
- (13) methylethcathinone (MEC);
- (14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
- (15) dimethylmethcathinone (DMMC);

- (16) fluoroamphetamine;
 (17) fluoromethamphetamine;
 (18) α -methylaminobutyrophenone (MABP or buphedrone);
 (19) ~~β -keto-N-methylbenzodioxolylpropylamine (bk-MBDB or~~
1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
 (20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
 (21) ~~naphthylpyrovalerone (naphyrone)~~ 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)
pentan-1-one (naphthylpyrovalerone or naphyrone);
 (22) ~~(RS)-1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP or~~
~~alpha-pyrrolidinovalerophenone~~ (alpha-pyrrolidinopentiophenone (alpha-PVP);
 (23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or
 MPHP); and
 (24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
 (25) 4-methyl-N-ethylcathinone (4-MEC);
 (26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
 (27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
 (28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
 (29) 4-fluoro-N-methylcathinone (4-FMC);
 (30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
 (31) alpha-pyrrolidinobutiophenone (α -PBP);
 (32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
 (33) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB); and
~~(24)~~ (34) any other substance, except bupropion or compounds listed under a
 different schedule, that is structurally derived from 2-aminopropan-1-one by substitution
 at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not
 the compound is further modified in any of the following ways:
 (i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
 haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
 system by one or more other univalent substituents;
 (ii) by substitution at the 3-position with an acyclic alkyl substituent;
 (iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
 methoxybenzyl groups; or
 (iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
 (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless
 specifically excepted or unless listed in another schedule, any natural or synthetic material,
 compound, mixture, or preparation that contains any quantity of the following substances,

their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of the isomers, esters, ethers, or salts is possible:

(1) marijuana;

(2) tetrahydrocannabinols naturally contained in a plant of the genus *Cannabis*, synthetic equivalents of the substances contained in the cannabis plant or in the resinous extractives of the plant, or synthetic substances with similar chemical structure and pharmacological activity to those substances contained in the plant or resinous extract, including, but not limited to, 1 *cis* or *trans* tetrahydrocannabinol, 6 *cis* or *trans* tetrahydrocannabinol, and 3,4 *cis* or *trans* tetrahydrocannabinol;

(3) synthetic cannabinoids, including the following substances:

(i) Naphthoylindoles, which are any compounds containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(*N*-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of naphthoylindoles include, but are not limited to:

(A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);

(B) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);

(C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);

(D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);

(E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);

(F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);

(G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);

(H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);

(I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);

(J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).

(ii) Naphthylmethylindoles, which are any compounds containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(*N*-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:

(A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);

(B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).

(iii) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the

pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent. Examples of naphthoylpyrroles include, but are not limited to, (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).

(iv) Naphthylmethylindenes, which are any compounds containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent. Examples of naphthylemethylindenes include, but are not limited to, E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).

(v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent. Examples of phenylacetylindoles include, but are not limited to:

(A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);

(B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);

(C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);

(D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).

(vi) Cyclohexylphenols, which are compounds containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not limited to:

(A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);

(B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (Cannabicyclohexanol or CP 47,497 C8 homologue);

(C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol (CP 55,940).

(vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or

10.1 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to
 10.2 any extent and whether or not substituted in the phenyl ring to any extent. Examples of
 10.3 benzoylindoles include, but are not limited to:

10.4 (A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);

10.5 (B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);

10.6 (C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone
 10.7 (WIN 48,098 or Pravadoline).

10.8 (viii) Others specifically named:

10.9 (A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
 10.10 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);

10.11 (B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
 10.12 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);

10.13 (C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
 10.14 -1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);

10.15 (D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);

10.16 (E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
 10.17 (XLR-11);

10.18 (F) 1-pentyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indazole-3-carboxamide
 10.19 (AKB-48(APINACA));

10.20 (G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
 10.21 (5-Fluoro-AKB-48);

10.22 (H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);

10.23 (I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro
 10.24 PB-22);

10.25 (J) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-
 10.26 3-carboxamide (AB-PINACA);

10.27 (K) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-
 10.28 1H-indazole-3-carboxamide (AB-FUBINACA);

10.29 (L) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-
 10.30 indazole-3-carboxamide(AB-CHMINACA);

10.31 (M) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-
 10.32 methylbutanoate (5-fluoro-AMB);

10.33 (N) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);

10.34 (O) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone
 10.35 (FUBIMINA);

11.1 (P) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo
 11.2 [2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);

11.3 (Q) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)
 11.4 -1H-indole-3-carboxamide (5-fluoro-ABICA);

11.5 (R) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
 11.6 -1H-indole-3-carboxamide;

11.7 (S) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
 11.8 -1H-indazole-3-carboxamide; and

11.9 (T) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)
 11.10 -3,3-dimethylbutanoate.

11.11 (i) A controlled substance analog, to the extent that it is implicitly or explicitly
 11.12 intended for human consumption.

11.13 Sec. 2. Minnesota Statutes 2014, section 152.02, subdivision 3, is amended to read:

11.14 Subd. 3. **Schedule II.** (a) Schedule II consists of the substances listed in this
 11.15 subdivision.

11.16 (b) Unless specifically excepted or unless listed in another schedule, any of
 11.17 the following substances whether produced directly or indirectly by extraction from
 11.18 substances of vegetable origin or independently by means of chemical synthesis, or by a
 11.19 combination of extraction and chemical synthesis:

11.20 (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium
 11.21 or opiate.

11.22 (i) Excluding:

11.23 (A) apomorphine;

11.24 (B) thebaine-derived butorphanol;

11.25 (C) dextrophan;

11.26 (D) nalbuphine;

11.27 (E) nalmefene;

11.28 (F) naloxegol;

11.29 ~~(F)~~ (G) naloxone;

11.30 ~~(G)~~ (H) naltrexone; and

11.31 ~~(H)~~ and (I) their respective salts;

11.32 (ii) but including the following:

11.33 (A) opium, in all forms and extracts;

11.34 (B) codeine;

11.35 (C) dihydroetorphine;

- 12.1 (D) ethylmorphine;
- 12.2 (E) etorphine hydrochloride;
- 12.3 (F) hydrocodone;
- 12.4 (G) hydromorphone;
- 12.5 (H) metopon;
- 12.6 (I) morphine;
- 12.7 (J) oxycodone;
- 12.8 (K) oxymorphone;
- 12.9 (L) thebaine;
- 12.10 (M) oripavine;
- 12.11 (2) any salt, compound, derivative, or preparation thereof which is chemically
- 12.12 equivalent or identical with any of the substances referred to in clause (1), except that
- 12.13 these substances shall not include the isoquinoline alkaloids of opium;
- 12.14 (3) opium poppy and poppy straw;
- 12.15 (4) coca leaves and any salt, cocaine compound, derivative, or preparation of coca
- 12.16 leaves (including cocaine and ecgonine and their salts, isomers, derivatives, and salts
- 12.17 of isomers and derivatives), and any salt, compound, derivative, or preparation thereof
- 12.18 which is chemically equivalent or identical with any of these substances, except that the
- 12.19 substances shall not include decocainized coca leaves or extraction of coca leaves, which
- 12.20 extractions do not contain cocaine or ecgonine;
- 12.21 (5) concentrate of poppy straw (the crude extract of poppy straw in either liquid,
- 12.22 solid, or powder form which contains the phenanthrene alkaloids of the opium poppy).
- 12.23 (c) Any of the following opiates, including their isomers, esters, ethers, salts, and
- 12.24 salts of isomers, esters and ethers, unless specifically excepted, or unless listed in another
- 12.25 schedule, whenever the existence of such isomers, esters, ethers and salts is possible
- 12.26 within the specific chemical designation:
- 12.27 (1) alfentanil;
- 12.28 (2) alphaprodine;
- 12.29 (3) anileridine;
- 12.30 (4) bezitramide;
- 12.31 (5) bulk dextropropoxyphene (nondosage forms);
- 12.32 (6) carfentanil;
- 12.33 (7) dihydrocodeine;
- 12.34 (8) dihydromorphinone;
- 12.35 (9) diphenoxylate;
- 12.36 (10) fentanyl;

- 13.1 (11) isomethadone;
- 13.2 (12) levo-alpha-acetylmethadol (LAAM);
- 13.3 (13) levomethorphan;
- 13.4 (14) levorphanol;
- 13.5 (15) metazocine;
- 13.6 (16) methadone;
- 13.7 (17) methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
- 13.8 (18) moramide - intermediate, 2-methyl-3-morpholino-1,
- 13.9 1-diphenyl-propane-carboxylic acid;
- 13.10 (19) pethidine;
- 13.11 (20) pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine;
- 13.12 (21) pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate;
- 13.13 (22) pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 13.14 (23) phenazocine;
- 13.15 (24) piminodine;
- 13.16 (25) racemethorphan;
- 13.17 (26) racemorphan;
- 13.18 (27) remifentanil;
- 13.19 (28) sufentanil;
- 13.20 (29) tapentadol;
- 13.21 (30) 4-Anilino-N-phenethyl-4-piperidine (ANPP).

13.22 (d) Unless specifically excepted or unless listed in another schedule, any material,
13.23 compound, mixture, or preparation which contains any quantity of the following
13.24 substances having a stimulant effect on the central nervous system:

- 13.25 (1) amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 13.26 (2) methamphetamine, its salts, isomers, and salts of its isomers;
- 13.27 (3) phenmetrazine and its salts;
- 13.28 (4) methylphenidate;
- 13.29 (5) lisdexamfetamine.

13.30 (e) Unless specifically excepted or unless listed in another schedule, any material,
13.31 compound, mixture, or preparation which contains any quantity of the following
13.32 substances having a depressant effect on the central nervous system, including its salts,
13.33 isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of
13.34 isomers is possible within the specific chemical designation:

- 13.35 (1) amobarbital;
- 13.36 (2) glutethimide;

- 14.1 (3) secobarbital;
- 14.2 (4) pentobarbital;
- 14.3 (5) phencyclidine;
- 14.4 (6) phencyclidine immediate precursors:
- 14.5 (i) 1-phenylcyclohexylamine;
- 14.6 (ii) 1-piperidinocyclohexanecarbonitrile;
- 14.7 (7) phenylacetone.
- 14.8 (f) Hallucinogenic substances: nabilone.

14.9 Sec. 3. Minnesota Statutes 2014, section 152.02, subdivision 4, is amended to read:

14.10 Subd. 4. **Schedule III.** (a) Schedule III consists of the substances listed in this
14.11 subdivision.

14.12 (b) Stimulants. Unless specifically excepted or unless listed in another schedule,
14.13 any material, compound, mixture, or preparation which contains any quantity of the
14.14 following substances having a potential for abuse associated with a stimulant effect on the
14.15 central nervous system, including its salts, isomers, and salts of such isomers whenever
14.16 the existence of such salts, isomers, and salts of isomers is possible within the specific
14.17 chemical designation:

- 14.18 (1) benzphetamine;
- 14.19 (2) chlorphentermine;
- 14.20 (3) clortermine;
- 14.21 (4) phendimetrazine.

14.22 (c) Depressants. Unless specifically excepted or unless listed in another schedule,
14.23 any material, compound, mixture, or preparation which contains any quantity of the
14.24 following substances having a potential for abuse associated with a depressant effect on
14.25 the central nervous system:

14.26 (1) any compound, mixture, or preparation containing amobarbital, secobarbital,
14.27 pentobarbital or any salt thereof and one or more other active medicinal ingredients which
14.28 are not listed in any schedule;

14.29 (2) any suppository dosage form containing amobarbital, secobarbital, pentobarbital,
14.30 or any salt of any of these drugs and approved by the food and drug administration for
14.31 marketing only as a suppository;

14.32 (3) any substance which contains any quantity of a derivative of barbituric acid, or
14.33 any salt of a derivative of barbituric acid, except those substances which are specifically
14.34 listed in other schedules;

(4) any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the federal Food, Drug, and Cosmetic Act;

(5) any of the following substances:

(i) chlorhexadol;

(ii) ketamine, its salts, isomers and salts of isomers;

(iii) lysergic acid;

(iv) lysergic acid amide;

(v) methyprylon;

(vi) sulfondiethylmethane;

(vii) sulfonethylmethane;

(viii) sulfonmethane;

(ix) tiletamine and zolazepam and any salt thereof;

(x) embutramide;

(xi) Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl)-1,2-Dihydropyridin-3-yl) benzonitrile].

(d) Nalorphine.

(e) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as follows:

(1) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

(2) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

~~(3) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;~~

~~(4) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;~~

~~(5)~~ (3) not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

16.1 ~~(6)~~ (4) not more than 300 milligrams of ethylmorphine per 100 milliliters or not
 16.2 more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients
 16.3 in recognized therapeutic amounts;

16.4 ~~(7)~~ (5) not more than 500 milligrams of opium per 100 milliliters or per 100 grams,
 16.5 or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic
 16.6 ingredients in recognized therapeutic amounts;

16.7 ~~(8)~~ (6) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams
 16.8 with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

16.9 (f) Anabolic steroids ~~and~~, human growth hormone, and chorionic gonadotropin.

16.10 (1) Anabolic steroids, for purposes of this subdivision, means any drug or hormonal
 16.11 substance, chemically and pharmacologically related to testosterone, other than estrogens,
 16.12 progestins, corticosteroids, and dehydroepiandrosterone, and includes:

- 16.13 (i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane;
- 16.14 (ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;
- 16.15 (iii) androstanedione (5[alpha]-androstan-3,17-dione);
- 16.16 (iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene;
- 16.17 (v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene);
- 16.18 (vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);
- 16.19 (vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);
- 16.20 (viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione);
- 16.21 (ix) 4-androstenedione (androst-4-en-3,17-dione);
- 16.22 (x) 5-androstenedione (androst-5-en-3,17-dione);
- 16.23 (xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);
- 16.24 (xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one);
- 16.25 (xiii) boldione (androsta-1,4-diene-3,17-dione);
- 16.26 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);
- 16.27 (xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);
- 16.28 (xvi) dehydrochloromethyltestosterone
- 16.29 (4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one);
- 16.30 (xvii) desoxymethyltestosterone
- 16.31 (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol);
- 16.32 (xviii) [delta]1-dihydrotestosterone-
- 16.33 (17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);
- 16.34 (xix) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one);
- 16.35 (xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one);
- 16.36 (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene);

- 17.1 (xxii) fluoxymesterone
- 17.2 (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one);
- 17.3 (xxiii) formebolone
- 17.4 (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one);
- 17.5 (xxiv) furazabol
- 17.6 (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)13[beta]-ethyl-17[beta]
- 17.7 -hydroxygon-4-en-3-one;
- 17.8 (xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one);
- 17.9 (xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one);
- 17.10 (xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-3-one);
- 17.11 (xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-3-one);
- 17.12 (xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one);
- 17.13 (xxx) methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene);
- 17.14 (xxxi) methasterone (2 alpha-17 alpha-dimethyl-5 alpha-androst-17beta-ol-3-one)
- 17.15 ~~(xxxii)~~ (xxxii) methenolone
- 17.16 (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);
- 17.17 ~~(xxxiii)~~ (xxxiii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-androstane;
- 17.18 ~~(xxxiiii)~~ (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;
- 17.19 ~~(xxxv)~~ (xxxv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene;
- 17.20 ~~(xxxvi)~~ (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone
- 17.21 (17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);
- 17.22 ~~(xxxvii)~~ (xxxvii) methyldienolone
- 17.23 (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);
- 17.24 ~~(xxxviii)~~ (xxxviii) methyltrienolone
- 17.25 (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);
- 17.26 ~~(xxxix)~~ (xxxix) methyltestosterone
- 17.27 (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one);
- 17.28 ~~(xl)~~ (xl) mibolerone
- 17.29 (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one);
- 17.30 ~~(xli)~~ (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
- 17.31 (17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one);
- 17.32 ~~(xlii)~~ (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one);
- 17.33 ~~(xliii)~~ (xliii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene;
- 17.34 ~~(xliv)~~ (xliv) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol
- 17.35 (3[beta],17[beta]-dihydroxyestr-5-ene);
- 17.36 ~~(xlv)~~ (xlv) 3[alpha],17[beta]-dihydroxyestr-5-ene);

- 18.1 ~~(xlv)~~ (xlvi) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
- 18.2 ~~(xlv)~~ (xlvii) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- 18.3 ~~(xlvii)~~ (xlviii) norbolethone
- 18.4 (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one);
- 18.5 ~~(xlviii)~~ (xlix) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);
- 18.6 ~~(xlix)~~ (l) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one);
- 18.7 ~~(l)~~ (li) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);
- 18.8 ~~(li)~~ (lii) oxandrolone
- 18.9 (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one);
- 18.10 ~~(lii)~~ (liii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one);
- 18.11 ~~(liii)~~ (liv) oxymetholone
- 18.12 (17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one);
- 18.13 (lv) prostanazol (17 beta-hydroxy-5 alpha-androstano[3,2-C]pyrazole
- 18.14 ~~(liv)~~ (lvi) stanozolol
- 18.15 (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole);
- 18.16 ~~(lv)~~ (lvii) stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one);
- 18.17 ~~(lvi)~~ (lviii) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic
- 18.18 acid lactone);
- 18.19 ~~(lvii)~~ (lix) testosterone (17[beta]-hydroxyandrost-4-en-3-one);
- 18.20 ~~(lviii)~~ (lx) tetrahydrogestrinone
- 18.21 (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one);
- 18.22 ~~(lix)~~ (lxi) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one);
- 18.23 ~~(lx)~~ (lxii) any salt, ester, or ether of a drug or substance described in this paragraph.
- 18.24 Anabolic steroids are not included if they are: (A) expressly intended for administration
- 18.25 through implants to cattle or other nonhuman species; and (B) approved by the United
- 18.26 States Food and Drug Administration for that use;
- 18.27 (2) Human growth hormones.
- 18.28 (3) Chorionic gonadotropin.
- 18.29 (g) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and encapsulated
- 18.30 in a soft gelatin capsule in a United States Food and Drug Administration approved product.
- 18.31 (h) Any material, compound, mixture, or preparation containing the following
- 18.32 narcotic drug or its salt: buprenorphine.

18.33 Sec. 4. Minnesota Statutes 2014, section 152.02, subdivision 5, is amended to read:

18.34 Subd. 5. **Schedule IV.** (a) Schedule IV consists of the substances listed in this

18.35 subdivision.

19.1 (b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,
19.2 any material, compound, mixture, or preparation containing any of the following narcotic
19.3 drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
19.4 as follows:

19.5 (1) not more than one milligram of difenoxin and not less than 25 micrograms of
19.6 atropine sulfate per dosage unit;

19.7 (2) dextropropoxyphene (Darvon and Darvocet);

19.8 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical
19.9 and geometric isomers, and salts of these isomers (including tramadol).

19.10 (c) Depressants. Unless specifically excepted or unless listed in another schedule,
19.11 any material, compound, mixture, or preparation containing any quantity of the following
19.12 substances, including its salts, isomers, and salts of isomers whenever the existence of the
19.13 salts, isomers, and salts of isomers is possible:

19.14 (1) Alfaxalone (5 α -pregnan-3 α -ol-11,20-dione);

19.15 ~~(1)~~ (2) alprazolam;

19.16 ~~(2)~~ (3) barbital;

19.17 ~~(3)~~ (4) bromazepam;

19.18 ~~(4)~~ (5) camazepam;

19.19 ~~(5)~~ (6) carisoprodol;

19.20 ~~(6)~~ (7) chloral betaine;

19.21 ~~(7)~~ (8) chloral hydrate;

19.22 ~~(8)~~ (9) chlordiazepoxide;

19.23 ~~(9)~~ (10) clobazam;

19.24 ~~(10)~~ (11) clonazepam;

19.25 ~~(11)~~ (12) clorazepate;

19.26 ~~(12)~~ (13) clotiazepam;

19.27 ~~(13)~~ (14) cloxazolam;

19.28 ~~(14)~~ (15) delorazepam;

19.29 ~~(15)~~ (16) diazepam;

19.30 ~~(16)~~ (17) dichloralphenazone;

19.31 ~~(17)~~ (18) estazolam;

19.32 ~~(18)~~ (19) ethchlorvynol;

19.33 ~~(19)~~ (20) ethinamate;

19.34 ~~(20)~~ (21) ethyl loflazepate;

19.35 ~~(21)~~ (22) fludiazepam;

19.36 ~~(22)~~ (23) flurazepam;

20.1 (24) fospropofol
 20.2 ~~(23)~~ (25) halazepam;
 20.3 ~~(24)~~ (26) haloxazolam;
 20.4 ~~(25)~~ (27) ketazolam;
 20.5 ~~(26)~~ (28) lorazepam;
 20.6 ~~(27)~~ (29) lorazepam;
 20.7 ~~(28)~~ (30) lormetazepam mebutamate;
 20.8 ~~(29)~~ (31) medazepam;
 20.9 ~~(30)~~ (32) meprobamate;
 20.10 ~~(31)~~ (33) methohexital;
 20.11 ~~(32)~~ (34) methylphenobarbital;
 20.12 ~~(33)~~ (35) midazolam;
 20.13 ~~(34)~~ (36) nimetazepam;
 20.14 ~~(35)~~ (37) nitrazepam~~nordiazepam~~ nitrazepam;
 20.15 (38) nordiazepam;
 20.16 ~~(36)~~ (39) oxazepam;
 20.17 ~~(37)~~ (40) oxazolam;
 20.18 ~~(38)~~ (41) paraldehyde~~petrichloral~~ paraldehyde;
 20.19 (42) petrichloral;
 20.20 ~~(39)~~ (43) phenobarbital;
 20.21 ~~(40)~~ (44) pinazepam;
 20.22 ~~(41)~~ (45) prazepam;
 20.23 ~~(42)~~ (46) quazepam;
 20.24 (47) Suvorexant;
 20.25 ~~(43)~~ (48) temazepam;
 20.26 ~~(44)~~ (49) tetrazepam;
 20.27 ~~(45)~~ (50) triazolam;
 20.28 ~~(46)~~ (51) zaleplon;
 20.29 ~~(47)~~ (52) zolpidem;
 20.30 ~~(48)~~ (53) zopiclone.

20.31 (d) Any material, compound, mixture, or preparation which contains any quantity of
 20.32 the following substance including its salts, isomers, and salts of such isomers, whenever
 20.33 the existence of such salts, isomers, and salts of isomers is possible: fenfluramine.

20.34 (e) Stimulants. Unless specifically excepted or unless listed in another schedule,
 20.35 any material, compound, mixture, or preparation which contains any quantity of the

21.1 following substances having a stimulant effect on the central nervous system, including its
21.2 salts, isomers, and salts of isomers:

- 21.3 (1) cathine (norpseudoephedrine);
- 21.4 (2) diethylpropion;
- 21.5 (3) fencamfamine;
- 21.6 (4) fenproporex;
- 21.7 (5) mazindol;
- 21.8 (6) mefenorex;
- 21.9 (7) modafinil;
- 21.10 (8) pemoline (including organometallic complexes and chelates thereof);
- 21.11 (9) phentermine;
- 21.12 (10) pipradol;
- 21.13 (11) sibutramine;
- 21.14 (12) SPA (1-dimethylamino-1,2-diphenylethane).
- 21.15 (f) lorcaserin.

21.16 Sec. 5. Minnesota Statutes 2014, section 152.02, subdivision 6, is amended to read:

21.17 Subd. 6. **Schedule V; restrictions on methamphetamine precursor drugs.** (a) As
21.18 used in this subdivision, the following terms have the meanings given:

21.19 (1) "methamphetamine precursor drug" means any compound, mixture, or
21.20 preparation intended for human consumption containing ephedrine or pseudoephedrine as
21.21 its sole active ingredient or as one of its active ingredients; and

21.22 (2) "over-the-counter sale" means a retail sale of a drug or product but does not
21.23 include the sale of a drug or product pursuant to the terms of a valid prescription.

21.24 (b) The following items are listed in Schedule V:

21.25 (1) any compound, mixture, or preparation containing any of the following limited
21.26 quantities of narcotic drugs, which shall include one or more nonnarcotic active medicinal
21.27 ingredients in sufficient proportion to confer upon the compound, mixture or preparation
21.28 valuable medicinal qualities other than those possessed by the narcotic drug alone:

21.29 (i) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
21.30 grams;

21.31 (ii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
21.32 grams;

21.33 (iii) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms
21.34 of atropine sulfate per dosage unit;

21.35 (iv) not more than 100 milligrams of opium per 100 milliliters or per 100 grams; or

22.1 (v) not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of
22.2 atropine sulfate per dosage unit.

22.3 (2) Stimulants. Unless specifically exempted or excluded or unless listed in another
22.4 schedule, any material, compound, mixture, or preparation that contains any quantity of
22.5 the following substance having a stimulant effect on the central nervous system, including
22.6 its salts, isomers, and salts of isomers: pyrovalerone.

22.7 (3) Depressants. Unless specifically exempted or excluded or unless listed in another
22.8 schedule, any material, compound, mixture, or preparation that contains any quantity
22.9 of the following substance having a depressant effect on the central nervous system,
22.10 including its salts, isomers, and salts of isomers:

22.11 (i) ezogabine;

22.12 (~~ii~~) pregabalin;

22.13 (~~iii~~) lacosamide.

22.14 (4) Any compound, mixture, or preparation containing ephedrine or pseudoephedrine
22.15 as its sole active ingredient or as one of its active ingredients.

22.16 (c) No person may sell in a single over-the-counter sale more than two packages of a
22.17 methamphetamine precursor drug or a combination of methamphetamine precursor drugs or
22.18 any combination of packages exceeding a total weight of six grams, calculated as the base.

22.19 (d) Over-the-counter sales of methamphetamine precursor drugs are limited to:

22.20 (1) packages containing not more than a total of three grams of one or
22.21 more methamphetamine precursor drugs, calculated in terms of ephedrine base or
22.22 pseudoephedrine base; or

22.23 (2) for nonliquid products, sales in blister packs, where each blister contains not
22.24 more than two dosage units, or, if the use of blister packs is not technically feasible, sales
22.25 in unit dose packets or pouches.

22.26 (e) A business establishment that offers for sale methamphetamine precursor drugs
22.27 in an over-the-counter sale shall ensure that all packages of the drugs are displayed
22.28 behind a checkout counter where the public is not permitted and are offered for sale only
22.29 by a licensed pharmacist, a registered pharmacy technician, or a pharmacy clerk. The
22.30 establishment shall ensure that the person making the sale requires the buyer:

22.31 (1) to provide photographic identification showing the buyer's date of birth; and

22.32 (2) to sign a written or electronic document detailing the date of the sale, the name
22.33 of the buyer, and the amount of the drug sold.

22.34 A document described under clause (2) must be retained by the establishment for
22.35 at least three years and must at all reasonable times be open to the inspection of any
22.36 law enforcement agency.

23.1 Nothing in this paragraph requires the buyer to obtain a prescription for the drug's
23.2 purchase.

23.3 (f) No person may acquire through over-the-counter sales more than six grams of
23.4 methamphetamine precursor drugs, calculated as the base, within a 30-day period.

23.5 (g) No person may sell in an over-the-counter sale a methamphetamine precursor
23.6 drug to a person under the age of 18 years. It is an affirmative defense to a charge under
23.7 this paragraph if the defendant proves by a preponderance of the evidence that the
23.8 defendant reasonably and in good faith relied on proof of age as described in section
23.9 340A.503, subdivision 6.

23.10 (h) A person who knowingly violates paragraph (c), (d), (e), (f), or (g) is guilty of
23.11 a misdemeanor and may be sentenced to imprisonment for not more than 90 days, or to
23.12 payment of a fine of not more than \$1,000, or both.

23.13 (i) An owner, operator, supervisor, or manager of a business establishment that
23.14 offers for sale methamphetamine precursor drugs whose employee or agent is convicted of
23.15 or charged with violating paragraph (c), (d), (e), (f), or (g) is not subject to the criminal
23.16 penalties for violating any of those paragraphs if the person:

23.17 (1) did not have prior knowledge of, participate in, or direct the employee or agent to
23.18 commit the violation; and

23.19 (2) documents that an employee training program was in place to provide the
23.20 employee or agent with information on the state and federal laws and regulations regarding
23.21 methamphetamine precursor drugs.

23.22 (j) Any person employed by a business establishment that offers for sale
23.23 methamphetamine precursor drugs who sells such a drug to any person in a suspicious
23.24 transaction shall report the transaction to the owner, supervisor, or manager of the
23.25 establishment. The owner, supervisor, or manager may report the transaction to local law
23.26 enforcement. A person who reports information under this subdivision in good faith is
23.27 immune from civil liability relating to the report.

23.28 (k) Paragraphs (b) to (j) do not apply to:

23.29 (1) pediatric products labeled pursuant to federal regulation primarily intended for
23.30 administration to children under 12 years of age according to label instructions;

23.31 (2) methamphetamine precursor drugs that are certified by the Board of Pharmacy as
23.32 being manufactured in a manner that prevents the drug from being used to manufacture
23.33 methamphetamine;

23.34 (3) methamphetamine precursor drugs in gel capsule or liquid form; or

23.35 (4) compounds, mixtures, or preparations in powder form where pseudoephedrine
23.36 constitutes less than one percent of its total weight and is not its sole active ingredient.

24.1 (l) The Board of Pharmacy, in consultation with the Department of Public Safety,
24.2 shall certify methamphetamine precursor drugs that meet the requirements of paragraph
24.3 (k), clause (2), and publish an annual listing of these drugs.

24.4 (m) Wholesale drug distributors licensed and regulated by the Board of Pharmacy
24.5 pursuant to sections 151.42 to 151.51 and registered with and regulated by the United
24.6 States Drug Enforcement Administration are exempt from the methamphetamine precursor
24.7 drug storage requirements of this section.

24.8 (n) This section preempts all local ordinances or regulations governing the sale
24.9 by a business establishment of over-the-counter products containing ephedrine or
24.10 pseudoephedrine. All ordinances enacted prior to the effective date of this act are void.